Audentes Therapeutics Inc (BOLD) Receives Consensus Rating of “Hold” from Brokerages

Shares of Audentes Therapeutics Inc (NASDAQ:BOLD) have been assigned an average recommendation of “Hold” from the fifteen brokerages that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $34.56.

A number of research firms have issued reports on BOLD. ValuEngine cut Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday. Zacks Investment Research cut shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 9th. Mizuho upgraded shares of Audentes Therapeutics from a “neutral” rating to a “buy” rating and set a $26.00 price objective on the stock in a research note on Wednesday, August 8th. Raymond James restated a “hold” rating on shares of Audentes Therapeutics in a research note on Wednesday, August 8th. Finally, BidaskClub cut shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, October 5th.

BOLD stock opened at $27.69 on Friday. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of -8.14 and a beta of 0.73. Audentes Therapeutics has a 1 year low of $24.51 and a 1 year high of $46.18.

Audentes Therapeutics (NASDAQ:BOLD) last posted its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.07). On average, equities research analysts anticipate that Audentes Therapeutics will post -3.33 EPS for the current fiscal year.

In related news, Director Louis G. Lange sold 33,000 shares of Audentes Therapeutics stock in a transaction dated Monday, September 24th. The stock was sold at an average price of $37.38, for a total transaction of $1,233,540.00. Following the transaction, the director now directly owns 365,999 shares of the company’s stock, valued at $13,681,042.62. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Suyash Prasad sold 10,000 shares of Audentes Therapeutics stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $36.88, for a total value of $368,800.00. Following the transaction, the vice president now directly owns 100 shares in the company, valued at $3,688. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 77,039 shares of company stock worth $2,925,260. Company insiders own 6.60% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in BOLD. Wells Fargo & Company MN grew its holdings in Audentes Therapeutics by 803.8% during the first quarter. Wells Fargo & Company MN now owns 307,537 shares of the biotechnology company’s stock worth $9,242,000 after acquiring an additional 273,511 shares during the period. Swiss National Bank grew its holdings in Audentes Therapeutics by 31.3% during the first quarter. Swiss National Bank now owns 43,600 shares of the biotechnology company’s stock worth $1,310,000 after acquiring an additional 10,400 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in Audentes Therapeutics by 31.8% during the first quarter. Schwab Charles Investment Management Inc. now owns 45,597 shares of the biotechnology company’s stock worth $1,371,000 after acquiring an additional 11,000 shares during the period. American International Group Inc. grew its holdings in Audentes Therapeutics by 15.9% during the first quarter. American International Group Inc. now owns 12,829 shares of the biotechnology company’s stock worth $386,000 after acquiring an additional 1,761 shares during the period. Finally, Northern Trust Corp grew its holdings in Audentes Therapeutics by 21.5% during the first quarter. Northern Trust Corp now owns 248,969 shares of the biotechnology company’s stock worth $7,482,000 after acquiring an additional 44,102 shares during the period. 96.74% of the stock is currently owned by hedge funds and other institutional investors.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Read More: Market Capitalization – What it Means for Investors

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply